OR WAIT null SECS
December 14, 2022
Under the collaboration between Vertex and Entrada, the companies will work on discovering and developing intracellular endosomal escape vehicle therapeutics for myotonic dystrophy type 1.
December 13, 2022
Amgen’s $27.8 billion acquisition of Horizon Therapeutics, an Irish biotechnology company, is one of the largest of 2022.
Takeda will purchase the rights to Nimbus Pharmaceuticals candidate, NDI-034858, which is currently being evaluated for treating multiple autoimmune diseases.
December 12, 2022
Generate Biomedicines published a preprint describing technology that can generate novel proteins towards desired functional or other properties.
PictorLabs, a digital pathology company developing an AI-powered virtual staining platform, formally announced its launch at the start of December.
The R&D analytical solutions will consist of analytical lab services that use USP’s in-house scientific expertise and state-of-the-art facilities at the USP Advanced Manufacturing Technology Lab in Richmond and the USP headquarters facility in Rockville, Md.
December 07, 2022
Ferring Pharmaceuticals’ Rebyota was approved for the prevention of recurrence of Clostridioides difficile infection.
December 05, 2022
In addition, personnel, equipment, and facilities from the acquired companies will expand Reaction Biology’s presence in Germany while enabling its global customers to leverage Bioassay’s expansive portfolio of regulated clinical and commercial services.
December 01, 2022
Results from Eisai and Biogen’s Alzheimer's treatment, lecanemab, indicated significantly slowed cognitive decline in patients relative to placebo.
Merck will use BigHat’s AI/machine learning-enabled platform to design candidates for up to three drug discovery programs.